Original Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2011; 17(6): 708-716
Published online Feb 14, 2011. doi: 10.3748/wjg.v17.i6.708
Table 1 Demographics and characteristics of patients enrolled in this study
CharacteristicsTotalCHLCHCCP-value
CH vs LCCH vs HCCLC vs HCC
n (%)179 (100.0)64 (35.8)65 (36.3)50 (27.9)---
Gender (male/female) (% male)129/50 (72.1)38/26 (59.4)47/18 (72.3)44/6 (88.0)0.121< 0.0010.040
Age (yr, mean ± SD)45.8 ± 12.339.7 ± 13.349.9 ± 10.848.4 ± 9.5< 0.001< 0.0010.495
AFP [ng/mL, median (min-max)]13.2 (0.1-3 295 000.0)3.2 (0.1-5039.0)11.8 (1.0-444 718.0)704.8 (1.2-3 295 000.0)< 0.001< 0.001< 0.001
AST [IU/L, median (min-max)]66.0 (7.0-3618.0)39.5 (7.0-481.0)66.0 (15.0-297.0)138.0 (9.0-3618.0)< 0.001< 0.001< 0.001
ALT [IU/L, median (min-max)]50.0 (1.0-860.0)47 (6-748)46 (9-216)64 (1-860)0.4800.4810.123
AST/ALT1.28 (0.1-120.6)0.9 (0.1-2.9)1.4 (0.2-6.0)2.1 (0.1-120.6)< 0.001< 0.001< 0.001
Serum HBV DNA (log10 IU/mL, mean ± SD)5.6 ± 2.06.1 ± 2.15.8 ± 1.44.6 ± 2.20.334< 0.0010.003
All HBeAg(+), (%)71 (39.7)36 (56.3)19 (29.2)16 (32.0)0.0020.0100.749
All HBeAg(-), (%)108 (60.3)28 (43.8)46 (70.8)34 (68.0)
HBeAg(+); HBeAb(-), (%)71 (39.7)36 (56.3)19 (29.2)16 (32.0)0.0020.0100.749
HBeAg(-); HBeAb(+), (%)86 (48.0)22 (34.4)40 (61.5)24 (48.0)0.0020.1410.039
HBeAg(-); HBeAb(-), (%)22 (12.3)6 (9.4)6 (9.2)10 (20.0)0.9780.1050.098
Genotype
B, n (%)132 (73.7)47 (73.4)48 (73.8)37 (74.0)0.9580.9460.985
C, n (%)47 (26.3)17 (26.6)17 (26.2)13 (26.0)
Table 2 Comparison of hepatitis B e antigen (+) and hepatitis B e antigen (-) patients
CharacteristicsTotalHBeAg(+)HBeAg(-)P-value
n (%)179 (100.0)71 (39.7)108 (60.3)-
Gender (male/female) (% male)129/50 (72.1)47/24 (66.2)82/26 (75.9)0.106
Age (yr, mean ± SD)45.8 ± 12.340.7 ± 11.549.2 ± 11.7< 0.001
AFP [ng/mL, median (min-max)]13.2 (0.1-3 295 000.0)10.9 (0.2-230472.0)19.9 (0.1-3 295 000.0)0.008
AST [IU/L, median (min-max)]66.0 (7.0-3618.0)55.0 (12.0-635.0)71.0 (7.0-3618.0)0.028
ALT [IU/L, median (min-max)]50.0 (1.0-860.0)47.0 (1.0-748.0)52.0 (6.0-860.0)0.535
AST/ALT1.3 (0.1-120.6)1.1 (0.1-30.8)1.4 (1.4-120.6)0.022
Serum HBV DNA (log10 IU/mL, mean ± SD)5.6 ± 2.06.5 ± 1.85.0 ± 1.9< 0.001
< 20 000 IU/mL, n (%)40 (22.3)6 (8.5)34 (31.5)< 0.001
≥ 20 000 IU/mL, n (%)139 (77.7)65 (91.5)74 (68.5)
Clinical status
CH, n (%)64 (35.8)36 (50.7)28 (25.9)0.003
LC, n (%)65 (36.3)19 (26.8)46 (42.6)
HCC, n (%)50 (27.9)16 (22.5)34 (31.5)
Genotype
B, n (%)132 (73.7)50 (70.4)82 (75.9)0.259
C, n (%)47 (26.3)21 (29.6)26 (24.1)
Table 3 Comparison of patients with hepatitis B e antigen (+), before and after hepatitis B e antigen seroconversion
CharacteristicsGroup 1
Group 2
Group 3
P-value
HBeAg(+), HBeAb(-)HBeAg(-), HBeAb(+)HBeAg(-), HBeAb(-)1 vs 21 vs 32 vs 3
n (%)71 (39.7)86 (48.0)22 (12.3)---
Gender (male/female) (% male)47/24 (66.2)71/15 (82.6)11/11 (50.0)0.0180.1710.001
Age (yr, mean ± SD)40.7 ± 11.549.8 ± 11.946.9 ± 10.6< 0.0010.0280.296
AFP [ng/mL, median (min-max)]10.9 (0.2-230 472.0)17.1 (0.1-3 295 000.0)40.8 (0.4-514 412.0)0.0160.0480.731
AST [IU/L, median (min-max)]55.0 (12.0-635.0)68.0 (7.0-3618.0)76.5 (9.0-580.0)0.0170.5360.448
ALT [IU/L, median (min-max)]47.0 (1.0-748.0)60.0 (9.0-860.0)43.0 (6.0-154.0)0.2000.1730.023
AST/ALT1.1 (0.1-30.8)1.3 (0.1-120.6)1.7 (0.5-6.0)0.0910.0070.052
Serum HBV DNA (log10 IU/mL, mean ± SD)6.5 ± 1.85.1 ± 1.84.5 ± 2.4< 0.001< 0.0010.146
< 20 000 IU/mL, n (%)6 (8.5)25 (29.1)9 (40.9)0.001< 0.0010.286
≥ 20 000 IU/mL, n (%)65 (91.5)61 (70.9)13 (59.1)
Clinical status
CH, n (%)36 (50.7)22 (25.6)6 (27.3)0.0010.0540.871
LC, n (%)19 (26.8)40 (46.5)6 (27.3)0.0110.9630.104
HCC, n (%)16 (22.5)24 (27.9)10 (45.4)0.4420.0360.114
Genotype
B, n (%)50 (70.4)66 (76.7)16 (72.7)0.3690.8350.694
C, n (%)21 (29.6)20 (23.3)6 (27.3)
Table 4 Precore and core promoter mutations in patients with hepatitis B e antigen (+), before and after hepatitis B e antigen seroconversion n (%)
AllGroup 1
Group 2
Group 3
Group 2+3
P-value
HBeAg(+), HBeAb(-)HBeAg(-), HBeAb(+)HBeAg(-), HBeAb(-)HBeAg(-)1 vs 21 vs 32 vs 31 vs (2+3)
T1762/A17641
Absent90 (50.3)42 (59.2)38 (44.2)10 (45.5)48 (44.4)0.0620.2580.9150.054
Present89 (49.7)29 (40.8)48 (55.8)12 (54.5)60 (55.6)
A18962
Absent65 (61.3)48 (100.0)315 (34.9)2 (13.3)17 (29.3)< 0.001< 0.0010.114< 0.001
Present41 (38.7)0 (0.0)28 (65.1)13 (87.7)41 (70.7)
A18992
Absent81 (76.4)43 (89.6)27 (62.8)11 (73.3)38 (65.5)0.0030.0340.1160.004
Present25 (23.6)5 (10.4)16 (37.2)4 (26.7)20 (34.5)
T1762/A1764 and A18962
Absent88 (83.0)48 (100.0)31 (72.1)9 (60.0)40 (68.9)< 0.001< 0.0010.383< 0.001
Present18 (17.0)0 (0.0)12 (27.9)6 (40.0)18 (31.0)
T1762/A1764 or A18962
Absent33 (31.1)31 (64.6)2 (4.7)0 (0.0)2 (1.9)4< 0.001< 0.0010.395< 0.001
Present73 (68.9)17 (35.4)41 (95.3)15 (100.0)56 (98.1)
Table 5 Precore and core promoter mutations in samples with hepatitis B e antigen (-) and hepatitis B e antibody (-)
No.Sample IDT1762/A1764A1896A1899Serum HBV DNA (log10 IU/mL)
107.10.068YesNoNo4.59
208.70.091YesNoNo4.87
308.100.038YesYesNo6.43
407.10.121YesYesNo7.52
508.10.002YesYesNo7.18
609.41.591YesYesYes6.53
709.40.037YesYesYes5.62
810.80.004YesYesNo2.78
906.10.062NoYesNo3.32
1008.10.086NoYesNo4.94
1109.40.033NoYesNo7.28
1209.80.040NoYesNo4.05
1309.41.806NoYesYes7.42
1407.10.070NoYesYes4.72
1509.80.037NoYesYes6.78
1608.10.016YesNANA5.21
1708.10.020YesNANA-0.37
1808.10.039YesNANA3.10
19P.X00.34YesNANA-0.54
2007.10.117NoNANA1.73
2107.10.026NoNANA1.27
2207.10.173NoNANA3.48
Table 6 Precore and core promoter mutations related to serum hepatitis B virus DNA and alanine aminotransferase in hepatitis B e antigen (+) patients
Serum HBV DNA (log10 IU/mL) (mean ± SD) (n)
P-valueALT (IU/L) [median (min-max)] (n)
P-value
AbsentPresentAbsentPresent
T1762/A176417.14 ± 1.46 (42)5.60 ± 1.99 (29)< 0.00143.5 (13.0-748.0) (42)48.5 (1.0-215.0) (29)0.806
A189626.98 ± 1.27 (48)--47.0 (1.0-748.0) (48)--
A189927.01 ± 1.25 (43)6.68 ± 1.53 (5)0.60945.5 (1.0-748.0) (43)55.0 (36.0-92.0) (5)0.627
T1762/A1764 and A189626.98 ± 1.27 (48)--47.0 (1.0-748.0) (48)--
T1762/A1764 or A189627.33 ± 1.23 (31)6.33 ± 1.08 (17)0.01150.0 (15.0-748.0) (31)41.5 (1.0-117.0) (17)0.459
Table 7 Precore and core promoter mutations related to serum hepatitis B virus DNA and alanine aminotransferase in hepatitis B e antigen (-) patients
Serum HBV DNA (log10 IU/mL) (mean ± SD) (n)
P-valueALT (IU/L) [median (min-max)] (n)
P-value
AbsentPresentAbsentPresent
T1762/A176414.64 ± 2.00 (48)5.23 ± 1.79 (60)0.09557.0 (6.0-302) (48)51.5 (6.0-860.0) (60)0.885
A189625.44 ± 1.66 (17)5.91 ± 1.35 (41)0.23146.0 (15.0-860.0) (17)63.5 (14.0-302.0) (41)0.321
A189925.80 ± 1.29 (38)5.72 ± 1.76 (20)0.38252.0 (14.0-860.0) (38)58.5 (17.0-302.0) (20)0.693
T1762/A1764 and A189625.59 ± 1.51 (40)6.17 ± 1.27 (18)0.13865.0 (14.0-860.0) (40)51.0 (17.0-174.0) (18)0.543
T1762/A1764 or A189622.77 ± 4.31 (2)5.88 ± 1.23 (56)< 0.00159.5 (23.0-96.0) (2)52.0 (42.0-860.0) (56)0.847

  • Citation: Utama A, Siburian MD, Purwantomo S, Intan MDB, Kurniasih TS, Gani RA, Achwan WA, Arnelis, Lelosutan SA, Lukito B, Harmono T, Zubir N, Julius, Soemohardjo S, Lesmana LA, Sulaiman A, Tai S. Association of core promoter mutations of hepatitis B virus and viral load is different in HBeAg(+) and HBeAg(-) patients. World J Gastroenterol 2011; 17(6): 708-716
  • URL: https://www.wjgnet.com/1007-9327/full/v17/i6/708.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v17.i6.708